Compare RJET & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJET | SLDB |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | 8400 | 121 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.0M | 932.9M |
| IPO Year | 2009 | 2017 |
| Metric | RJET | SLDB |
|---|---|---|
| Price | $17.42 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $16.36 |
| AVG Volume (30 Days) | 65.6K | ★ 825.9K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.43 | ★ 34.97 |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $1,676,500,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.84 | ★ N/A |
| Revenue Growth | ★ 13.74 | N/A |
| 52 Week Low | $15.37 | $3.79 |
| 52 Week High | $26.70 | $11.45 |
| Indicator | RJET | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 37.66 |
| Support Level | $16.81 | $6.25 |
| Resistance Level | $20.65 | $8.67 |
| Average True Range (ATR) | 0.60 | 0.44 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 19.13 | 9.05 |
Republic Airways Holdings Inc is a regional airline mainly in North America. The company provides scheduled passenger service through its mainline partnerships with American Airlines, Delta Air Lines, and United Airlines. Republic offers scheduled passenger service on several daily flights to various cities in the United States, Canada, Mexico, and the Caribbean. It exclusively operates the dual-class Embraer E170/175 family of aircraft, and provides its services under the American Eagle, Delta Connection, or United Express brands. The company is organized and operates as one operating and reportable segment: regional airline services.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.